Alkem Labs slumps over 5% despite record interim dividend

Alkem Laboratories

declared an interim dividend of ₹43 a share, the highest in the company's history. However, the stock was down over 5% in trade due to modest growth in the latest third quarter ended December 2025.

The Mumbai-based pharmaceuticals company also revealed a plan to acquire a majority stake in Occlutech Holding, a loss-making Swiss company that manufactures minimally invasive cardiac devices valued at €180 million, for cash before June 30, 2026.



Net profit rose 1.6% year-over-year to ₹636 crore from ₹625.8 crore, in line with estimates.

Revenue climbed 10.7% to ₹3,737 crore compared to ₹3,374 crore last year, driven by revenue from international markets.

Earnings before interest, tax, depreciation, and amortisation (EBITDA) increased 9% to ₹826.8 crore from ₹759.2 crore, though margins dipped marginally to 22.1% versus 22.5%.

Track the latest corporate earnings here.